Overview

The ORTIZ Study: Optimising RASi Therapy With SZC

Status:
Not yet recruiting

Trial end date:
2022-08-15

Target enrollment:

Participant gender:

Summary

The hypothesis is that 3 months' treatment with SZC versus placebo will enable RASi (Irbesartan) maximisation in a cohort of patients with diabetic kidney disease.

Phase:

Phase 2

Details

Lead Sponsor:

Barts & The London NHS Trust